Gareth W. Fearnley

Gareth W. Fearnley

Auto-generated profile, based on publicly available information

Gareth W. Fearnley

Babraham Institute

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
CBCharlie Bridgewood
Charlie Bridgewood
GFGareth W. Fearnley
Gareth W. Fearnley
ABAnna Berekmeri
Anna Berekmeri
PLPhilip Laws
Philip Laws
TMTom Macleod
Tom Macleod
MWMiriam Wittmann
Miriam Wittmann
The IL-1 family member cytokine IL-36γ is recognised as key mediator in the immunopathology of psoriasis, hallmarks of which involve the activation of both resident and infiltrating inflammatory myeloid cells and aberrant angiogenesis. This research demonstrates a role for IL-36γ in both myeloid activation and angiogenesis. We show that IL-36γ induces the production of psoriasis-associated cytokines from macrophages (IL-23 and TNFα) and that this response is enhanced in macrophages from psoriasis patients. This effect is specific for IL-36γ and could not be mimicked by other IL-1 family cytokines such as IL-1α. IL-36γ was also demonstrated to induce endothelial tube formation and branching, in a VEGF-A-dependent manner. Furthermore, IL-36γ-stimulated macrophages potently activated endothelial cells and led to increased adherence of monocytes, effects that were markedly more pronounced for psoriatic macrophages. Interestingly, regardless of stimulus, psoriasis monocytes showed increased adherence to both the stimulated and unstimulated endothelium when compared with monocytes from healthy individuals. Collectively, these findings show that IL-36γ has the potential to enhance endothelium directed leucocyte infiltration into the skin and strengthen the IL-23/IL-17 pathway adding to the growing evidence of pathogenetic roles for IL-36γ in psoriatic responses. Our findings also point to a cellular response, which could potentially explain cardiovascular comorbidities in psoriasis in the form of endothelial activation and increased monocyte adherence.

4 April 2016 in Biology Open
Verified
Journal Article
Open access
PDF file
GFGareth W. Fearnley
Gareth W. Fearnley
GSGina A. Smith
Gina A. Smith
IAIzma Abdul-Zani
Izma Abdul-Zani
NYNadira Yusupovna Yuldasheva
Nadira Yusupovna Yuldasheva
NMNadeem A. Mughal
Nadeem A. Mughal
Sreenivasan PonnambalamSreenivasan Ponnambalam
Sreenivasan Ponnambalam
Vascular endothelial growth factor A (VEGF-A) binding to the receptor tyrosine kinase VEGFR2 triggers multiple signal transduction pathways, which regulate endothelial cell responses that control vascular development. Multiple isoforms of VEGF-A can elicit differential signal transduction and endothelial responses. However, it is unclear how such cellular responses are controlled by isoform-specific VEGF-A–VEGFR2 complexes. Increasingly, there is the realization that the membrane trafficking of receptor–ligand complexes influences signal transduction and protein turnover. By building on these concepts, our study shows for the first time that three different VEGF-A isoforms (VEGF-A165, VEGF-A121 and VEGF-A145) promote distinct patterns of VEGFR2 endocytosis for delivery into early endosomes. This differential VEGFR2 endocytosis and trafficking is linked to VEGF-A isoform-specific signal transduction events. Disruption of clathrin-dependent endocytosis blocked VEGF-A isoform-specific VEGFR2 activation, signal transduction and caused substantial depletion in membrane-bound VEGFR1 and VEGFR2 levels. Furthermore, such VEGF-A isoforms promoted differential patterns of VEGFR2 ubiquitylation, proteolysis and terminal degradation. Our study now provides novel insights into how different VEGF-A isoforms can bind the same receptor tyrosine kinase and elicit diverse cellular outcomes.

14 April 2015 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Closed access
PDF file
GSGina A. Smith
Gina A. Smith
GFGareth W. Fearnley
Gareth W. Fearnley
MHMichael A. Harrison
Michael A. Harrison
DTDarren Charles Tomlinson
Darren Charles Tomlinson
SWStephen B. Wheatcroft
Stephen B. Wheatcroft
Sreenivasan PonnambalamSreenivasan Ponnambalam
Sreenivasan Ponnambalam

29 September 2015 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
GSGina Anne Smith
Gina Anne Smith
GFGareth W. Fearnley
Gareth W. Fearnley
DTDarren Charles Tomlinson
Darren Charles Tomlinson
MHMichael A. Harrison
Michael A. Harrison
Sreenivasan PonnambalamSreenivasan Ponnambalam
Sreenivasan Ponnambalam
VEGFs (vascular endothelial growth factors) are a family of conserved disulfide-linked soluble secretory glycoproteins found in higher eukaryotes. VEGFs mediate a wide range of responses in different tissues including metabolic homoeostasis, cell proliferation, migration and tubulogenesis. Such responses are initiated by VEGF binding to soluble and membrane-bound VEGFRs (VEGF receptor tyrosine kinases) and co-receptors. VEGF and receptor splice isoform diversity further enhances complexity of membrane protein assembly and function in signal transduction pathways that control multiple cellular responses. Different signal transduction pathways are simultaneously activated by VEGFR–VEGF complexes with membrane trafficking along the endosome–lysosome network further modulating signal output from multiple enzymatic events associated with such pathways. Balancing VEGFR–VEGF signal transduction with trafficking and proteolysis is essential in controlling the intensity and duration of different intracellular signalling events. Dysfunction in VEGF-regulated signal transduction is important in chronic disease states including cancer, atherosclerosis and blindness. This family of growth factors and receptors is an important model system for understanding human disease pathology and developing new therapeutics for treating such ailments.

29 March 2019 in eLife
Verified
Journal Article
Open access
GFGareth W Fearnley
Gareth W Fearnley
KYKatherine A Young
Katherine A Young
JEJames Edgar
James Edgar
RARobin Antrobus
Robin Antrobus
IHIain M Hay
Iain M Hay
HSHayley J Sharpe
Hayley J Sharpe
Cell-cell communication in multicellular organisms depends on the dynamic and reversible phosphorylation of protein tyrosine residues. The receptor-linked protein tyrosine phosphatases (RPTPs) receive cues from the extracellular environment and are well placed to influence cell signaling. However, the direct events downstream of these receptors have been challenging to resolve. We report here that the homophilic receptor PTPRK is stabilized at cell-cell contacts in epithelial cells. By combining interaction studies, quantitative tyrosine phosphoproteomics, proximity labeling and dephosphorylation assays we identify high confidence PTPRK substrates. PTPRK directly and selectively dephosphorylates at least five substrates, including Afadin, PARD3 and δ-catenin family members, which are all important cell-cell adhesion regulators. In line with this, loss of PTPRK phosphatase activity leads to disrupted cell junctions and increased invasive characteristics. Thus, identifying PTPRK substrates provides insight into its downstream signaling and a potential molecular explanation for its proposed tumor suppressor function.

15 August 2014 in Molecular Biology of the Cell
Verified
Journal Article
Open access
GFGareth W. Fearnley
Gareth W. Fearnley
AOAdam F. Odell
Adam F. Odell
ALAntony M. Latham
Antony M. Latham
NMNadeem A. Mughal
Nadeem A. Mughal
ABAlexander F. Bruns
Alexander F. Bruns
Sreenivasan PonnambalamSreenivasan Ponnambalam
Sreenivasan Ponnambalam
Vascular endothelial growth factor A (VEGF-A) regulates many aspects of vascular physiology. VEGF-A stimulates signal transduction pathways that modulate endothelial outputs such as cell migration, proliferation, tubulogenesis, and cell–cell interactions. Multiple VEGF-A isoforms exist, but the biological significance of this is unclear. Here we analyzed VEGF-A isoform–specific stimulation of VCAM-1 gene expression, which controls endothelial–leukocyte interactions, and show that this is dependent on both ERK1/2 and activating transcription factor-2 (ATF-2). VEGF-A isoforms showed differential ERK1/2 and p38 MAPK phosphorylation kinetics. A key feature of VEGF-A isoform–specific ERK1/2 activation and nuclear translocation was increased phosphorylation of ATF-2 on threonine residue 71 (T71). Using reverse genetics, we showed ATF-2 to be functionally required for VEGF-A–stimulated endothelial VCAM-1 gene expression. ATF-2 knockdown blocked VEGF-A–stimulated VCAM-1 expression and endothelial–leukocyte interactions. ATF-2 was also required for other endothelial cell outputs, such as cell migration and tubulogenesis. In contrast, VCAM-1 was essential only for promoting endothelial–leukocyte interactions. This work presents a new paradigm for understanding how soluble growth factor isoforms program complex cellular outputs and responses by modulating signal transduction pathways.